The activation of the urokinase-type plasminogen activator and its receptor system is associated with retinal diseases. Among peptide inhibitors of this system, UPARANT acts by preventing the onset of pathologic signs of neovascular ocular diseases. We investigated whether systemic UPARANT may act in a therapeutic regimen by suppressing the retinal damage that characterizes diabetic retinopathy using a rat model of streptozotocin-induced diabetes.
The urokinase receptor-derived peptide UPARANT recovers dysfunctional electroretinogram and blood-retinal barrier leakage in a rat model of diabetes / Cammalleri, Maurizio; Locri, Filippo; Marsili, Stefania; Dal Monte, Massimo; Pisano, Claudio; Mancinelli, Angelo; Lista, Liliana; Rusciano, Dario; De Rosa, Mario; Pavone, Vincenzo; Bagnoli, Paola. - In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. - ISSN 0146-0404. - 58:7(2017), pp. 3138-3148. [10.1167/iovs.17-21593]
The urokinase receptor-derived peptide UPARANT recovers dysfunctional electroretinogram and blood-retinal barrier leakage in a rat model of diabetes
PISANO, CLAUDIO;Lista, Liliana;De Rosa, Mario;Pavone, Vincenzo;
2017
Abstract
The activation of the urokinase-type plasminogen activator and its receptor system is associated with retinal diseases. Among peptide inhibitors of this system, UPARANT acts by preventing the onset of pathologic signs of neovascular ocular diseases. We investigated whether systemic UPARANT may act in a therapeutic regimen by suppressing the retinal damage that characterizes diabetic retinopathy using a rat model of streptozotocin-induced diabetes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
